Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $278,625.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph P. Lyssikatos sold 12,500 shares of the company's stock in a transaction on Monday, July 21st. The stock was sold at an average price of $22.29, for a total transaction of $278,625.00. Following the completion of the transaction, the insider owned 952,688 shares of the company's stock, valued at $21,235,415.52. This trade represents a 1.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Enliven Therapeutics Trading Down 3.4%

ELVN stock traded down $0.75 on Friday, hitting $21.20. The company had a trading volume of 183,614 shares, compared to its average volume of 497,197. Enliven Therapeutics, Inc. has a 12-month low of $13.30 and a 12-month high of $30.03. The stock's 50-day simple moving average is $20.41 and its 200 day simple moving average is $20.19. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of -11.04 and a beta of 0.83.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06). Research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Wall Street Analyst Weigh In

ELVN has been the subject of several analyst reports. HC Wainwright upped their price target on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research report on Wednesday, July 2nd. The Goldman Sachs Group initiated coverage on shares of Enliven Therapeutics in a research note on Monday, June 16th. They issued a "buy" rating and a $37.00 price target for the company. Robert W. Baird increased their price target on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday, June 16th. Finally, Jones Trading decreased their price target on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $41.20.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ELVN. Invesco Ltd. raised its position in shares of Enliven Therapeutics by 3.5% during the 4th quarter. Invesco Ltd. now owns 15,072 shares of the company's stock valued at $339,000 after purchasing an additional 508 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Enliven Therapeutics by 3.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company's stock valued at $451,000 after purchasing an additional 718 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock valued at $36,000 after purchasing an additional 1,114 shares during the period. MetLife Investment Management LLC raised its position in shares of Enliven Therapeutics by 6.3% during the 4th quarter. MetLife Investment Management LLC now owns 21,746 shares of the company's stock valued at $489,000 after purchasing an additional 1,285 shares during the period. Finally, California State Teachers Retirement System raised its position in shares of Enliven Therapeutics by 10.2% during the 4th quarter. California State Teachers Retirement System now owns 20,914 shares of the company's stock valued at $471,000 after purchasing an additional 1,940 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.